table network network 2
demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 severe or critically
COVID 19 outpatients
bamlanivimab/etesevimab BLAZE-1 phase 2 ... BLAZE-1 phase 3 ...

2 studies excluded by filtering options 0

6528 BLAZE-4, 0 110risk of bias not avaialble
8968 OPTIMISE-C19 (bamlanivimab-etesevimab vs casirivimab-imdevimab), 2021 113high risk of bias

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons